5/19/2016 05:32 pm

(Stockwatch) May 18, 2016 - ImmunoGen, Inc. today reported the clinical data from a 46-patient Phase 1 cohort evaluating the efficacy and safety of mirvetuximab soravtansine as single-agent therapy for platinum-resistant, folate receptor alpha (FRa)-positive ovarian cancer.

4/27/2016 05:12 pm

(Boston Business Journal/BioFlash blog) Apr 26, 2016 - One of the area’s largest developers of cancer drugs, ImmunoGen, has named a former Shire and Genzyme executive as its new CEO.

4/18/2016 04:33 pm

(TheStreet) Apr 18, 2016 - Novel CD33-targeting product candidate is the first antibody-drug conjugate (ADC) to employ an IGN, a new type of cancer-killing agent; Phase 1 study in acute myeloid leukemia (AML) is designed to efficiently inform the IMGN779 development pathway.

4/5/2016 04:27 pm

(ImmunoGen) Apr 5, 2016 - ImmunoGen, Inc. a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, age 63, has decided to retire from his positions of President and CEO of the Company.

3/1/2016 11:04 am

(Flatiron Health) Mar 1, 2016 — Flatiron Health and West Cancer Center today announced that West Cancer Center selected OncoEMR® and OncoAnalytics® to enhance the delivery of high quality evidence-based care, support participation in alternative payment models and better manage clinical workflows.

2/9/2016 11:04 am

(University of Montreal News) Feb 9, 2016 - North American researchers have identified drugs that showed promising perspectives in treating cancers, according to a recent study published in Cancer Research.

2/4/2016 06:09 pm

(Boston Business Journal/BioFlash blog) Feb 4, 2016 - ImmunoGen says that in coming months it plans to test its experimental cancer drug in combination with Merck’s drug, Keytruda, after mouse trials done internally at the company — confirmed by academic studies — show the two drugs may multiply each others' effects.

2/4/2016 01:33 pm

(ImmunoGen) Feb 4, 2016 - ImmunoGen's mirvetuximab soravtansine folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) to be assessed in combination with Merck's anti-PD-1 therapy.

1/26/2016 05:45 pm

(ImmunoGen) Jan 26, 2016 - ImmunoGen, Inc. today announced the Company earned a milestone payment with Bayer's initiation of a global Phase 2 clinical study designed to support registration of anetumab ravtansine (BAY 94-9343).

1/11/2016 05:13 pm

(Benzinga) Jan 10, 2016 - ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced recent product program advancements and anticipated 2016 events in advance of the 34th Annual J.P. Morgan Healthcare Conference.

12/2/2015 12:01 pm

(CNNMoney) Dec 2, 2015 - Critical Outcome Technologies Inc. announced today that it submitted an Orphan Drug Application intended for the treatment of Li-Fraumeni Syndrome (LFS) to the U.S. Food and Drug Administration (FDA) for its lead cancer drug candidate, COTI-2.

12/2/2015 12:00 pm

(Xconomy San Francisco) Dec 2, 2015 - Rich Heyman twice made hay developing drugs to treat cancers that depend on hormones to thrive. Now he’s trying it again with a new company markedly different than the previous two.

12/2/2015 12:00 pm

(Yahoo! Finance) Dec 2, 2015 - Guided Therapeutics, Inc., the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it believes it has reached a general agreement with the U.S. Food and Drug Administration (FDA) on a plan for submitting an approvable application for the LuViva® Advanced Cervical Scan.

12/2/2015 12:00 pm

(Abcodia) Dec 2, 2015 - Abcodia Ltd, a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer, announced today the availability of the ROCA® Test for use by physicians in five U.S. states: Arizona, Illinois, Massachusetts, New Jersey and Texas.

12/2/2015 12:00 pm

(RAPS) Dec 1, 2015 - As quality issues with screen-film mammography continue to crop up, the US Food and Drug Administration (FDA) says facilities are almost done transitioning to full field digital mammography (FFDM) units 15 years after they came into clinical use.

12/2/2015 12:00 pm

(Yahoo! Finance) Dec 2, 2015 - Exact Sciences Corp. announced that the Centers for Medicare and Medicaid Services (CMS) indicated that it is correcting the 2016 Clinical Laboratory Fee Schedule (CLFS) and will include the reimbursement national limitation amount (NLA) for Cologuard at $493.21.

12/2/2015 11:05 am

(TheStreet) Dec 2, 2015 - Preliminary data from COMET, a phase 2 randomized trial sponsored by Novocure, show that the use of Tumor Treating Fields (TTFields) therapy is safe in the treatment of brain metastases originating from non-small cell lung cancer (NSCLC).

12/2/2015 11:05 am

(MarketWatch) Dec 2, 2015 - Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced that the initial results from a Phase 2 study demonstrated that DPX-Survivac can induce a strong immune response in diffuse large B cell lymphoma (DLBCL) tumors.

12/2/2015 11:05 am

(Kite Pharma) Dec 2, 2015 - Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT(TM)) products for the treatment of cancer, today announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with r/r ALL.

12/2/2015 11:05 am

(MarketWatch) Dec 1, 2015 - Final results expected in second half of 2016.

12/2/2015 11:05 am

(MD Anderson) Dec 2, 2015 - Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC).

12/2/2015 11:05 am

(Forbes) Dec 2, 2015 - IBM and a large hospital system in India have partnered to diagnose and treat cancer care in a country of 1.2 billion residents who often cannot access oncologists, leaving their diseases undetected and untreated.

12/2/2015 11:04 am

(Medscape/Reuters Health) Dec 2, 2015 - Adding prostate and pelvic radiotherapy (RT) to hormone therapy appears to cut relapse rates in men newly diagnosed with high-risk nonmetastatic (M0) node-positive prostate cancer, according to an exploratory analysis by European investigators.

12/2/2015 11:04 am

(Reuters Health) Nov 30, 2015 - Mindfulness-based therapy may help ease anxiety and depression in some patients with cancer, a small research review suggests.

12/2/2015 11:04 am

(Novartis) Dec 2, 2015 - Novartis will present data that highlight advancements in targeted combination therapy research, and underscore the company's continued commitment to bringing innovative treatments to patients living with advanced breast cancer at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), December 8-12.

11/9/2015 01:08 pm

(TheStreet) Nov 8, 2015 - Ovarian cancer patients with tumors expressing high levels of a specific protein on their surface respond best to treatment with ImmunoGen's "smart bomb" cancer drug.

10/22/2015 04:42 pm

(Reuters) Oct 22, 2015 - ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study.

8/18/2015 12:02 pm

(New York Times/The Upshot) Aug 17, 2015 - One of the chief limitations of randomized trials is that they’re typically focused on narrow populations that meet strict criteria — those most likely to benefit from treatment.

7/15/2015 11:04 am

(ASCO) July 13, 2015 - The American Society of Clinical Oncology (ASCO) today issued an update to its 2006 clinical practice guideline on the use of white blood cell growth factors (also known as hematopoietic colony-stimulating factors, CSFs). The agents are given to lower the risk of low white blood cell counts and fever (febrile neutropenia) associated with certain types of chemotherapy.

6/30/2015 12:02 pm

(TheStreet) June 29, 2015 - Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.

6/16/2015 11:05 am

(UPI.com) June 15, 2015 - A molecule derived from avocados targets leukemia stem cells.

6/1/2015 11:06 pm

(TheStreet) June 1, 2015 - The perception that ImmunoGen can't develop a drug successfully on its own will probably improve Monday when post-ASCO trading kicks in.

5/30/2015 11:32 pm

(StreetInsider) May 30, 2015 - ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting of the first clinical findings in a disease-specific patient population with the Company’s unique, FR-targeting ADC, mirvetuximab soravtansine (abstract #5518).

5/15/2015 05:59 pm

(NCCN) May 15, 2015 - The NCCN Oncology Research Program (ORP) has received a $2-million grant from ImmunoGen, Inc. to facilitate preclinical and clinical research with mirvetuximab soravtansine for folate receptor alpha-positive cancers at NCCN Member Institutions and their affiliate community hospitals.

5/14/2015 06:14 pm

(MarketWatch) May 13, 2015 - Presentations to include initial findings with Company’s mirvetuximab soravtansine (IMGN853) for ovarian cancer and results from Roche’s MARIANNE trial with Kadcyla®.

5/6/2015 11:05 am

(ASCO) May 6, 2015 - The American Society of Clinical Oncology (ASCO) announced today the launch of PracticeNET, a collaborative network in which practices will share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO’s newly-formed Clinical Affairs Department.

4/28/2015 05:02 pm

(FoxBusiness/Associated Press) Apr 27, 2015 - Shares of cancer drugmaker ImmunoGen slumped Monday as Wall Street digested two hits to the company's drug development pipeline.

4/22/2015 11:03 am

(NASDAQ) Apr 22, 2015 - GlobeImmune, Inc. today announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination with radiation therapy in patients with chordoma is open for enrollment at the National Cancer Institute (NCI).

4/22/2015 11:03 am

(AACR) Apr 22, 2015 - The American Association for Cancer Research (AACR) and Richard Besser, MD, ABC News' chief health and medical editor, joined forces Tuesday afternoon on Besser's Twitter chat to share stories, observations, and significant research from the nation's top cancer researchers in conjunction with the AACR Annual Meeting, held April 18 to 22, in Philadelphia.

4/14/2015 12:01 pm

(PharmaTimes [UK]) Apr 13, 2015 - Seven new medicines have been accepted for use by the National Health Service in Scotland, including therapies for leukaemia, lung cancer and multiple sclerosis.